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Linear regression analyses were used for prediction of plasma catestatin
levels
Linear
regression
analysis
Dependent
variable: Plasma
catestatin level
Beta
(standardized) yP value
Beta
(standardized)
Independent
variables *P value
Age, years 0.006 0.277 0.041 0.201
Gender,
male
0.381 -0.133
HDL, mg/dL 0.381 -0.133 <0.001 0.390
Triglycerides,
mg/dL
0.381 -0.179
Hemoglobin
(mg/dL)
0.837 -0.028
Left
ventricular
mass (g)
0.189 -0.147
Constant 0.055 - 0.737 -
Adjusted R2 0.268 0.202
Linear regression analysis with enter method was used for all relevant independent variables
which were included if they were signiﬁcantly different in the univariate analyses*. In addition
the analysis was repeated after a pre-elimination with Stepwise method for the independent
variablesy.
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Objectıve: Atherosclerotic heart diseases continue to be the most important cause of
death in developed countries. Hyperlipidemia is the most crucial risk factor inC182 JACC Voatherosclerosis development. The statins used in hyperlipidemia treatment play an
essential role in reducing the morbidity and mortality associated with atherosclerosis.
There are numerous studies on old generation statins and new generation statins;
however, there are limited number of studies comparing these two groups. Therefore,
we aimed to present this study to the literature and determine the dose efﬁcacy of
hypolipidemic agents by comparing the old generation statin simvastatin to new
generation statins (atorvastatin, rosuvastatin).
Methods: This study is a clinical, prospective cohort study. A total of 160 subjects (76
women and 84 men) who applied to our clinic from November 2011 to May 2011 and
were indicated for medicinal treatment according to National Cholesterol Education
Programme Adult Treatment Panel (NCEP ATP) 3 criteria despite the four week long
ﬁrst line diet were included in the study. Following the evaluation of lipid proﬁles
based on medical history, physical examination, and clinical and laboratory ﬁndings,
eligible subjects were assigned to the three groups according to simvastatin dose (10
mg, 20 mg, 40 mg/day), three groups according to atorvastatin dose (10 mg, 20 mg, 40
mg/day) two groups according to rosuvastatin dose (10 mg, 20 mg/day). Thus, a total
of 8 groups were generated. There were 20 patients in each group. In our study, the
subjects were evaluated with clinical and laboratory methods at baseline and after 6
weeks of treatment.
Results: The mean age of the 160 patients enrolled for the study was 58.9510.22 (37
to 82). There was no difference between the groups with regards to demographic
characteristics. The reduction in low-density lipoprotein (LDL) cholesterol was 28-
40% (10-40 mg/day) with simvastatin, 39-51% (10-40 mg/day) with atorvastatin and
50-60% (10-20 mg/day) with rosuvastatin after 6 weeks of treatment (p<0.01). The
increase in high-density lipoprotein (HDL) cholesterol at week 6 compared to baseline
was most prominent in the rosuvastatin (20 mg/day) group.
Conclusıon: We detected that the hypolipidemic effects of rosuvastatin and ator-
vastatin were more prominent compared to simvastatin. This supports the idea that
new generation statins may be used in clinical practice to a further extent compared to
old generation statins. Furthermore, based on the ﬁndings of our study it can be
concluded that rosuvastatin may be the preferred choice of treatment in hyperlipidemia
patients with low levels of HDL-C.
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Coronary artery disease (CAD) is a chronic process that begins early in life and
progresses silently before becoming symptomatic. Besides scientiﬁcally based medical
treatment of this disease, patients frequently make use of alternative medicine. The
product sold as Clavis Panax that used by many people as a food supplements
according to the advertisements. Intake of a mixture of plant extracts may have serious
consequences in humans as drug interactions and side effects are unknown. Herein,
we report the case of a 58-year-old man who presented with chest pain. Due to typical
symptoms a coronary angiography and stent implantation was performed to the critical
lesions at the left anterior descending artery and right coronary artery successfully.
Initially his LDL level was 87 mg/dL, total cholesterol level was 154 mg/dL and
triglyceride level was 165 mg/dL. Three months later after he was discharged, he gave
up his medication and started to take an herbal drug called Clavis Panax. At the sixth
month after stent implantation, his LDL level was 224 mg/dL, total cholesterol was
388 mg/dL and triglyceride was 365 mg/dL. He was warned to stop taking Clavis and
was prescribed an increased dose of statin but he refused. He died of a myocardial
infarction in the eighth month after stent implantation.
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Because,dyslipidemia,inﬂammation and hypercoagulation are the major risk factors
for cardiovascular diseases we examined the Effects of CoQ10 supplementation on
serum lipoprotein, Il-6, ICAM-1 and plasma ﬁbrinogen in hyperlipidemic patients
with myocard infarction. In a double blind placebo controled clinical trial, 52
hyperlipidemic patients with myocard infarction and age range of 35-70 years were
randomly allocated to receive daily 200 mg coQ10 or placebo for 3 months. Fasting
blood, Physical activity and daily dietary intake were obtained at beginning and end of
3 months. SPSS version 18 were used for statistical analysis. At the end of study in
CoQ10 group,There were signiﬁcant decrease in total cholesterol (TC), Triglyceride
(TG), LDL-c, LDL-c/HDL-c and TC/HDL-c (p<0.05), IL-6 (p<0.001) and ICAM-1
(p<0.001) and signiﬁcant increase in HDL-c (p<0.05) compare to beginning of study.
At the end of study there were signiﬁcant decrease in LDL-c/HDL-c (p<0.05), TC/
HDL-c (p<0.05), IL-6 (p<0.001), ICAM-1 (P<0.001) and signiﬁcant increase in
HDL-c (p<0.05) compare to placebo group.We can conclude that 200 mg daily
CoQ10 for 3 months may have favorite effects on serum lipoproteins and inﬂam-
mation indicators but no effect on ﬁbrinogen and may be beneﬁcal in myocardial
infarction patients.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
